Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company that is dedicated to advancing innovative life-transforming therapeutics for individuals affected by genetically driven diseases. The company's proprietary FORCE™ platform enables the development of modern oligonucleotide therapeutics designed to overcome delivery limitations to muscle tissue. With a focus on serious muscle diseases, Dyne has a broad pipeline including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). Established in 2018, Dyne Therapeutics operates in the industries of Biotechnology, Health Care, and Pharmaceutical. The company's most recent milestone was a Post-IPO Equity investment on 21 May 2024. This investment underscores the confidence that investors place in Dyne Therapeutics' vision and potential for addressing unmet medical needs in the field of muscle diseases. For more information, visit https://www.dyne-tx.com. Overall, Dyne Therapeutics is positioned as an emerging force in the biotechnology and pharmaceutical sectors, with a strategic focus on delivering innovative therapies for individuals impacted by serious genetic muscle diseases.